News und Analysen
Here's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in November
Shares of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biotech rising like a phoenix from the ashes of Belviq's commercial flop, rose 10.6% in November, according to data from S&P Global....
3 High-Yield Dividend Stocks to Buy in 2018
Dividend investors on the hunt for above average income opportunities may want to place a heavy emphasis on pharmaceutical stocks next year. Despite the political turmoil surrounding the....
bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results
Shares of the clinical-stage biotech bluebird bio (NASDAQ: BLUE) rose by as much as 23.9% in pre-market trading today. The catalyst? The company reported that its CAR-T candidate, bb2121, produced....
The 3 Marijuana Stocks With the Most Cash on Their Balance Sheets
There aren't too many industries that can hold a candle to the returns of cryptocurrencies these days, but the marijuana industry isn't going down without a fight. Marijuana stocks certainly have....
Why 2018 Could Be the Best Year Yet for Cara Therapeutics
Most investors would be excited if one of the stocks they owned achieved a 45% gain in less than a year. But for Cara Therapeutics (NASDAQ: CARA) shareholders, that level of performance is....
2018 Is a Critical Year for These 3 Small Commercial-Stage Biotech Stocks
Making the leap from clinical-stage to the commercial-stage drug isn't easy. It requires an entirely different set of experience to navigate the world of private and public payers and a big....
You'll Be Stunned by How Many Cancer Immunotherapies Are Being Developed
For years, chemotherapy was the best treatment that the world of medicine had to offer in fighting cancer. That's no longer true. A powerful new class of cancer drugs called immunotherapies has....
Is Gilead Sciences, Inc. a Buy?
With only a few weeks remaining in 2017, Gilead Sciences (NASDAQ: GILD) stock price appears to be on course to finish roughly at the same level that it began the year. After getting off to a rocky....
Why Opko Health Stock Stumbled in November
Shares of Opko Health (NASDAQ: OPK) had another poor showing in November, with its stock shedding a whopping 19.5% of its value last month, according to data from S&P Global Market....
3 Growth Stocks I'd Buy Right Now
What's a six-letter word that's guaranteed to make investors happy? Growth. While growth comes in several flavors, they're all interrelated. Growth in revenue helps make earnings growth possible,....
Why Celldex Therapeutics Stock Reversed Course in November
Shares of the struggling small-cap biotech Celldex Therapeutics (NASDAQ: CLDX) finally showed some signs of life in November. Specifically, the biotech's stock rose by a healthy 27.6% last....
Better Buy: Pfizer (PFE) vs. AbbVie (ABBV)
For Pfizer (NYSE: PFE), 2017 so far has looked better than the past couple of years in terms of stock performance. However, the stock's 9% year-to-date gain isn't anything to jump up and down....
Is Now the Perfect Time to Buy Juno Therapeutics Stock?
Juno Therapeutics (NASDAQ: JUNO), a clinical-stage oncology company, continued its unrelenting rally this year by tacking on another $5 billion to its market cap in November, according to data....
The Individual Mandate: We Hate It, but We Need It
Big change is afoot in Washington, and it has nothing to do with the weather. Republicans in both houses of Congress have passed their respective version of tax reform and now are working on a few....
3 Top Stocks Under $10
There's cheap, then there's cheap. Some stocks are cheap in the sense of the definition of the word relating to relatively low price compared to their potential value. Others are cheap under....
Will Johnson & Johnson Raise Its Dividend in 2018?
Just about everyone has some products from Johnson & Johnson (NYSE: JNJ) in their medicine cabinets, ranging from over-the-counter medicines like Tylenol and Benadryl to Band-Aid bandages. Yet....
Better Buy: Intuitive Surgical, Inc. vs. Accuray, Inc.
New drugs that improve treatment often get a lot of attention. But in recent years some medical devices have arguably had just as much impact as many of these drugs. Two companies making such....
What Happened in the Stock Market Today
Stocks finished the week on a positive note Friday, with the Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) in positive territory throughout the session and....
Cantel Medical Corp. Keeps Pace on Its Goal
Cantel Medical (NYSE: CMD) reported results for the first quarter, posting double-digit revenue and earnings growth to start its fiscal year. It's hard to ask for more from the medical-supply....
What's Behind Valeant Pharmaceuticals Inc.'s 11% Move Higher?
Shares of Valeant Pharmaceuticals (NYSE: VRX), the embattled drugmaker that's predominantly grown through acquisitions and drug-price increases over the years, surged as much as 11% by 3 p.m. EST....
Here's Why Radius Health Is Rising Today
After presenting data from a phase 1 study at a medical conference, shares of Radius Health (NASDAQ: RDUS), a commercial-stage biotech focused on osteoporosis and cancer, rose 15% as of 11:15 a.m.....
Cantel Medical (CMD) Q1 2018 Earnings Conference Call Transcript
Image source: The Motley Fool.Cantel Medical (NYSE: CMD) Q1 2018 Earnings Conference CallDec. 7, 2017 11:00 a.m. ETOperatorContinue readingSource: Fool.com
Tax Reform Takes a Bite Out of Biotech Stocks
Healthcare companies will largely benefit from tax reform that lowers the statutory business tax rate to 20% from 35%, but those in research-intensive sectors such as biotechnology could end up....
A Game-Changing Breakthrough Could Be Coming for Hemophilia Patients
Patients diagnosed with hemophilia B suffer a lifetime of treatment, but that could change based on recently reported data from an early stage trial Pfizer (NYSE: PFE) and Spark Therapeutics....
Immunomedics' Data Is Good News for Seattle Genetics, Too
Seattle Genetics' (NASDAQ: SGEN) deal to license Immunomedics' (NASDAQ: IMMU) sacituzumab govitecan, a breast cancer drug, was shelved earlier this year when activist investor venBio Select....